Dr Lutz Jermutus

Lutz Jermutus is a Product Development Team Leader and Senior Director, R&D, in MedImmune’s Cardiovascular & Metabolic Diseases iMED, responsible for leading clinical drug candidates from late stage pre-clinical through IND to clinical proof-of-concept. His current focus is on a GLP-1/Glucagon co-agonist peptide for type 2 diabetes/obesity and an immune-suppressive fusion protein for new onset type 1 diabetes.
Both compounds originate from his previous role as global head of technology overseeing teams in Cambridge, UK, and Gaithersburg, MD. Here, Lutz’ activities included therapeutic peptides and proteins but also novel biologics modalities such as polyclonal antibodies, antibody-drug-conjugates, multi-functional antibodies, scaffolds and oligonucleotides. His team established a phenotypic selection and screening platform that delivered novel therapeutic targets across all disease areas and managed multiple technology collaborations with biotechs including Evotec, Direvo Biotech, PeptiDream, Molecular Partners, Silence Therapeutics, Xenome and Retrogenix. Previously at Cambridge Antibody Technology, Lutz was director of discovery, oncology, and director of protein engineering.
Following studies in chemical engineering in Karlsruhe (Germany) and biotechnology in Strasbourg (France), Lutz earned his doctorate at the University of Zurich (Switzerland) in biochemistry. He was a Kekulé-Fellow of the German Chemical Industry Association, a recipient of a fellowship at the German National Academic Foundation and in 2009 was admitted as Fellow of the Royal Society of Chemistry. In 2013, he was elected Industrial Fellow at Trinity Hall, University of Cambridge.

Lutz has published widely in the area of protein science and engineering, and is an inventor on numerous product (eg. tralokinumab, fresolimumab) and technology patents.